Tuxarin Er is a drug owned by Mainpointe Pharmaceuticals Llc. It is protected by 4 US drug patents filed in 2015. Out of these, 2 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 03, 2032. Details of Tuxarin Er's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9066942 | Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer |
Jan, 2032
(6 years from now) | Active |
| US9107921 | Oral dosage forms for oxygen containing active agents and oxyl-containing polymers |
Jan, 2032
(6 years from now) | Active |
| US6248363 | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
Nov, 2019
(5 years ago) |
Expired
|
| US6383471 | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
Apr, 2019
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tuxarin Er's patents.
Latest Legal Activities on Tuxarin Er's Patents
Given below is the list of recent legal activities going on the following patents of Tuxarin Er.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 08 Feb, 2023 | US9107921 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 01 Dec, 2022 | US9066942 |
| Surcharge for late Payment, Small Entity | 02 Jan, 2019 | US9066942 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 02 Jan, 2019 | US9066942 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 30 Nov, 2018 | US9107921 |
| Application ready for PDX access by participating foreign offices Critical | 31 Aug, 2015 | US9066942 |
| Application ready for PDX access by participating foreign offices Critical | 31 Aug, 2015 | US9107921 |
| Patent Issue Date Used in PTA Calculation Critical | 18 Aug, 2015 | US9107921 |
| Recordation of Patent Grant Mailed Critical | 18 Aug, 2015 | US9107921 |
| Email Notification Critical | 30 Jul, 2015 | US9107921 |
US patents provide insights into the exclusivity only within the United States, but Tuxarin Er is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tuxarin Er's family patents as well as insights into ongoing legal events on those patents.
Tuxarin Er's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tuxarin Er's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 03, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tuxarin Er Generics:
There are no approved generic versions for Tuxarin Er as of now.
About Tuxarin Er
Tuxarin Er is a drug owned by Mainpointe Pharmaceuticals Llc. It is used for treating cough and symptoms of upper respiratory allergies or the common cold. Tuxarin Er uses Chlorpheniramine Maleate; Codeine Phosphate as an active ingredient. Tuxarin Er was launched by Mainpointe in 2015.
Approval Date:
Tuxarin Er was approved by FDA for market use on 22 June, 2015.
Active Ingredient:
Tuxarin Er uses Chlorpheniramine Maleate; Codeine Phosphate as the active ingredient. Check out other Drugs and Companies using Chlorpheniramine Maleate; Codeine Phosphate ingredient
Treatment:
Tuxarin Er is used for treating cough and symptoms of upper respiratory allergies or the common cold.
Dosage:
Tuxarin Er is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 8MG;54.3MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |